Dave Miller

Currently serves as the Chief Scientific Officer at AustinPx, where he leads their pharmaceutics and analytical development teams and oversees the application of the KinetiSol Technology, which he co-invented. Specializing in formulation and processing technologies for improving the oral bioavailability of insoluble small molecules, Dave has applied his expertise toward advancing numerous drug candidates through all stages of development, from early discovery to line extensions, and he has published over 40 research articles in peer-reviewed journals, authored eight book chapters, and is co-editor of the First, Second, and Third Editions of the textbook Formulating Poorly Water-Soluble Drugs. He holds a B.S. in Chemical Engineering and a Ph.D. in Pharmaceutics from the University of Texas at Austin.